Clinical Trials Directory

Trials / Completed

CompletedNCT02198365

Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia

Comparison of Human Papillomavirus Integrated DNA and Messenger RNA for Detection and Prediction in Progression of Cervical Neoplasia

Status
Completed
Phase
Study type
Observational
Enrollment
250 (actual)
Sponsor
Cathay General Hospital · Academic / Other
Sex
Female
Age
20 Years – 80 Years
Healthy volunteers
Accepted

Summary

The investigators hypothesis is HPV integration could result in expression of oncogene transcripts, and not only constitutive expression but also the level of expression will be decisive for transformation and the maintenance of the malignant phenotype. Moreover, the expression and level of HPV viral transcripts not HPV DNA viral loads is correlated to the severity in cervical intraepithelial neoplasia (CIN) and cervical carcinomas (CxCa).

Detailed description

In the investigators proposal, the investigators will examine at least 250 baseline liquid-based cytology specimens from women with normal cytology, low-grade squamous intraepithelial lesions (LSILs), high-grade squamous intraepithelial lesions (HSILs), microinvasions and invasive cervical cancers. Specimens will be tested for HPV DNA using HPV blot and type-specific PCR including type 16, 18, 52, 58, 31, 33, 39, 45, 51, 56, 59, 68, 6, and 11. Cervical specimens from women with HPV DNA types 16, 18, 52, 58, 31 and 33, which are the most prevalent oncogenic types in Taiwan, will be examined for physical status of viral DNA tested by real-time PCR and FISH, along with level of expression in mRNA.

Conditions

Timeline

Start date
2007-01-01
Primary completion
2009-01-01
Completion
2009-03-01
First posted
2014-07-23
Last updated
2014-07-23

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02198365. Inclusion in this directory is not an endorsement.